ReviewCurrent opinion in pulmonary medicine2020
Precision medicine in severe pediatric asthma: opportunities and challenges.
Review in Current opinion in pulmonary medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Current Practices and Variations Among Pediatric Severe Asthma Programs in the United States-The North American Severe Pediatric Asthma Consortium.Pediatric pulmonology · 2026Observational
- Advancements in Biologic Therapies for Pediatric Asthma: Emerging Therapies and Future Directions.Cureus · 2025Review
- Future of biologics in pediatric asthma: Optimizing response, early introduction, and equitable access to treatment.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024Review
- Severe Asthma and Biological Therapies: Now and the Future.Journal of clinical medicine · 2023Review
- Translating Precision Health for Pediatrics: A Scoping Review.Children (Basel, Switzerland) · 2023Article
- Severe asthma in children: Description of a large multidisciplinary clinical cohort.Pediatric pulmonology · 2022Article
- Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy.ERJ open research · 2021Article
- Biologicals in childhood severe asthma: the European PERMEABLE survey on theERJ open research · 2021Article
- A System Pharmacology Multi-Omics Approach toward Uncontrolled Pediatric Asthma.Journal of personalized medicine · 2021Article
- Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction.Journal of asthma and allergy · 2021Review
- Defining a role for exercise training in the management of asthma.European respiratory review : an official journal of the European Respiratory Society · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewSevere pediatric asthma exerts a substantial burden on patients, their families and society. This review provides an update on the latest insights and needs regarding the implementation of precision medicine in severe pediatric asthma. RECENT
findingsBiologicals targeting underlying inflammatory pathways are increasingly available to treat children with severe asthma, holding the promise to enable precision medicine in this heterogeneous patient population with high unmet clinical needs. However, the current understanding of which child would benefit from which type or combination of biologicals is still limited, as most evidence comes from adult studies and might not be generalizable to the pediatric population. Studies in pediatric severe asthma are scarce due to the time-consuming effort to diagnose severe asthma and the challenge to recruit sufficient study participants. The application of innovative systems medicine approaches in international consortia might provide novel leads for - preferably noninvasive - new biomarkers to guide precision medicine in severe pediatric asthma. SUMMARY: Despite the increased availability of targeted treatments for severe pediatric asthma, clinical decision-making tools to guide these therapies are still lacking for the individual pediatric patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.